Symbiotic Capital Brings Together a World-Class Team of Scientists, Financiers and Entrepreneurs to Provide Credit Partnerships to Compelling Life Science Companies Around the World Symbiotic Capital Held Final Closing of its Inaugural Fund and Has Already Originated Hundreds of Millions of Dollars of Credit Facilities LOS ANGELES , Aug. 6, 2024 /PRNewswire/ -- Symbiotic Capital ("Symbiotic"), a global life science credit firm, was officially unveiled today with more than $600 million in capital committed and targeted for investments and co-investments. Symbiotic Capital is affiliated with Bellco Capital ("Bellco"), the Los Angeles -based investment firm founded by biotechnology entrepreneur Dr.
Arie Belldegrun. Symbiotic will structure and originate credit solutions to compelling life science companies to support scientific innovation across biotechnology, medical devices, diagnostics, tools, synthetic biology, and other healthcare subsectors. "The life science industry continues to experience unprecedented productivity, innovation and scientific discovery as biotechnology and technology converge," said Symbiotic Co-Chairman Dr.
Arie Belldegrun . "As the cost to research, develop and commercialize innovative therapeutics, devices, tools and other products has increased substantially throughout the sector, credit has become an increasingly important financing tool for established healthcare enterprises. With Symbiotic Capital, we have designed a science-first credit platform .